174 related articles for article (PubMed ID: 38153060)
21. [Pathogenesis, diagnosis and therapy of Legionella infections].
Lück PC; Steinert M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 May; 49(5):439-49. PubMed ID: 16596363
[TBL] [Abstract][Full Text] [Related]
22. Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes.
Smith RP; Baltch AL; Franke M; Hioe W; Ritz W; Michelsen P
J Antimicrob Chemother; 1997 Nov; 40(5):673-8. PubMed ID: 9421315
[TBL] [Abstract][Full Text] [Related]
23. Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates.
Bruin JP; Ijzerman EP; den Boer JW; Mouton JW; Diederen BM
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):103-8. PubMed ID: 22100012
[TBL] [Abstract][Full Text] [Related]
24. Use of the microbial growth curve in postantibiotic effect studies of Legionella pneumophila.
Smith RP; Baltch AL; Michelsen PB; Ritz WJ; Alteri R
Antimicrob Agents Chemother; 2003 Mar; 47(3):1081-7. PubMed ID: 12604545
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Shinzato T; Doyle E; Edelstein MA
Antimicrob Agents Chemother; 2001 Aug; 45(8):2204-9. PubMed ID: 11451675
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
Kashimoto Y; Kurosaka Y; Karibe Y; Uoyama S; Fujikawa K; Namba K; Otani T; Yamaguchi K
Jpn J Antibiot; 2009 Oct; 62(5):452-9. PubMed ID: 20055122
[TBL] [Abstract][Full Text] [Related]
27. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Sato T; Tateda K; Kimura S; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1594-7. PubMed ID: 21220530
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility of Legionella pneumophila Serogroups I--IV.
Saravolatz LD; Pohlod DJ; Quinn EL
Scand J Infect Dis; 1980; 12(3):215-9. PubMed ID: 7433921
[TBL] [Abstract][Full Text] [Related]
29. Sequence-based typing of Legionella pneumophila strains isolated from hospital water distribution systems as a complementary element of risk assessment of legionellosis in Poland.
Pancer K
Ann Agric Environ Med; 2013; 20(3):436-40. PubMed ID: 24069845
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of macrolides against intracellular Legionella pneumophila.
Segreti J; Meyer P; Kapell K
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):123-6. PubMed ID: 8902407
[TBL] [Abstract][Full Text] [Related]
31. In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.
Dubois J; Dubois M; Martel JF; Aubart K; Butler D
Antimicrob Agents Chemother; 2015 Jan; 59(1):707-10. PubMed ID: 25348534
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of Legionella pneumophila to antimicrobial agents and the presence of the efflux pump LpeAB.
Natås OB; Brekken AL; Bernhoff E; Hetland MAK; Löhr IH; Lindemann PC
J Antimicrob Chemother; 2019 Jun; 74(6):1545-1550. PubMed ID: 30815687
[TBL] [Abstract][Full Text] [Related]
33. Postantibiotic effect of various antibiotics on Legionella pneumophila strains isolated from water systems.
Birteksöz-Tan AS; Zeybek Z
Folia Microbiol (Praha); 2012 Nov; 57(6):495-9. PubMed ID: 22627604
[TBL] [Abstract][Full Text] [Related]
34. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.
Edelstein PH; Edelstein MA; Lehr KH; Ren J
J Antimicrob Chemother; 1996 Jan; 37(1):117-26. PubMed ID: 8647752
[TBL] [Abstract][Full Text] [Related]
35. Antibiotic Resistance of
Pappa O; Chochlakis D; Sandalakis V; Dioli C; Psaroulaki A; Mavridou A
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32796666
[TBL] [Abstract][Full Text] [Related]
36. DISTRIBUTION OF LEGIONELLA PNEUMOPHILA SEROGROUPS ISOLATED FROM WATER SYSTEMS OF PUBLIC FACILITIES IN BUSAN, SOUTH KOREA.
Hwang IY; Park EH; Park YK; Park SH; Sung GH; Park HY; Lee YC
Southeast Asian J Trop Med Public Health; 2016 May; 47(3):467-74. PubMed ID: 27405130
[TBL] [Abstract][Full Text] [Related]
37. Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila.
Barker J; Brown MR
J Antimicrob Chemother; 1995 Jul; 36(1):7-21. PubMed ID: 8537286
[TBL] [Abstract][Full Text] [Related]
38. Correlation of MIC value and disk inhibition zone diameters in clinical Legionella pneumophila serogroup 1 isolates.
Bruin JP; Diederen BM; Ijzerman EP; Den Boer JW; Mouton JW
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):339-42. PubMed ID: 23583350
[TBL] [Abstract][Full Text] [Related]
39. Virulence of Legionella pneumophila strains isolated from hospital water system and healthcare-associated Legionnaires' disease in Northern Italy between 2004 and 2009.
Ditommaso S; Giacomuzzi M; Rivera SR; Raso R; Ferrero P; Zotti CM
BMC Infect Dis; 2014 Sep; 14():483. PubMed ID: 25190206
[TBL] [Abstract][Full Text] [Related]
40. Environmental survey of Legionella pneumophila in hot springs in Taiwan.
Lin YE; Lu WM; Huang HI; Huang WK
J Toxicol Environ Health A; 2007 Jan; 70(1):84-7. PubMed ID: 17162501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
